Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Marc Cohen - aVenture Research

Marc Cohen

AddedMar 31, 2024

UpdatedOct 13, 2026

Marc Cohen

Marc Cohen

Founder, Cobro Ventures

Marc Cohen's Career

Cobro Ventures

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Investment FirmArlington, VA, US

Founder

C4 Therapeutics

Public$298.8MCambridge, MA, US

Board Member· Board

Co-Founder

Mana Therapeutics

Series A$49.5MArlington, VA, US

Co-Founder

Nextrna Therapeutics

Seed$56.1MBoston, MA, US

Board Member· Board

Co-Founder

Regenacy Pharmaceuticals

Public$17.1MWaltham, MA, US

Board Member· Board

Co-Founder

AI Proteins

Seed$18.2MBoston, MA, US

Co-Founder

OncoPep

Public$28.4MNorth Andover, MA, US

Co-Founder

People Similar to Marc Cohen

Jonathan RothbergBoard Member · 4Catalyzer

Abdulaziz ElgammalCo-Founder · Proteinea

Frances AnastassacosFounder · Nabla Bio

Surge BiswasFounder · Nabla Bio

Similar to Cobro Ventures

Cobalt VenturesMissouri, USest. 1999Cobalt VenturesMissouri, US · est. 1999

Cobalt Ventures: Blue Cross and Blue Shield's private equity subsidiary, investing in scalable healthcare firms.

Investment Firm3

Cobalt CapitalSanta Monica, CA, USest. 2019Cobalt CapitalSanta Monica, CA, US · est. 2019

Cobalt Capital, a multi-stage investment firm, accelerates growth of tech companies reshaping industries.

Investment Firm9

Cabra VCLimassol, Limassol District, CYest. 2016Cabra VCLimassol, Limassol District, CY · est. 2016

Cabra VC, LP: A global venture capital firm investing in start-up and seed stage tech companies.

Investment Firm5

Covera VenturesAustin, TX, USest. 2009Covera VenturesAustin, TX, US · est. 2009

Covera Ventures LP, a US-based venture capital firm, invests in infrastructure, software, and tech-enabled services.

Investment Firm8

Leadership at C4 Therapeutics

Andrew HirschCEO

Nathanael GrayBoard Member

Bruce DowneyBoard Member

Utpal KoppikarBoard Member

Hagop YoussoufianBoard Member

Glenn Russell DubinBoard Member

Similar to C4 Therapeutics

Beactica Therapeuticsest. 2006Beactica Therapeuticsest. 2006

Develops small molecule cancer therapeutics using targeted protein degradation and allosteric modulation platforms.

CAMP4 TherapeuticsCambridge, MA, USTherapeutics

Leadership at Mana Therapeutics

Mahmoud MahmoudianCEO

Patrick Hanley, Ph.D.Board Member

Similar to Mana Therapeutics

ManaT BioBaltimore, MD, USImmunotherapyest. 2020ManaT BioBaltimore, MD, US · est. 2020

Based in Baltimore, ManaT Bio is a biotech firm specializing in genetic and immunological therapies.

Series D · $72.1M50

Imvaq TherapeuticsNew York City, NY, USCancer Treatmentest. 2018Imvaq TherapeuticsNew York City, NY, US · est. 2018

Imvaq: A biotech firm innovating immuno-oncologics for global cancer treatment.

Series B · $20M8

Thunder BiotechProvo, UT, USCancer Treatmentest. 2016Thunder BiotechProvo, UT, US · est. 2016

Thunder Biotech: Innovating cancer treatment through biotechnology and immune system empowerment.

Series B · $24.4M23

Ernexa TherapeuticsCambridge, MA, USCell Therapiesest. 1984Ernexa TherapeuticsCambridge, MA, US · est. 1984

Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.

Public · $49.1M11

Leadership at Nextrna Therapeutics

Julia A NovinaCo-Founder

Dominique VerhelleCo-Founder

Bobby SandageBoard Member

Leon Wert-LamasCo-Founder

Similar to Nextrna Therapeutics

Redona TherapeuticsWatertown, MA, USCancer Treatmentest. 2016Redona TherapeuticsWatertown, MA, US · est. 2016

Redona Therapeutics: Advancing small molecule therapies for cancer via ncRNA modulation.

Series A · $66.8M24

Leadership at Regenacy Pharmaceuticals

Simon S. JonesCEO

Walter OgierBoard Member

Matthew JarpeCo-Founder

Similar to Regenacy Pharmaceuticals

Acylin TherapeuticsSeattle, WA, USPharmaceuticalsest. 2009Acylin TherapeuticsSeattle, WA, US · est. 2009

Acylin Therapeutics: Seattle-based biopharmaceutical developer specializing in acetylation inhibitors.

Series A · $6.4M9

RegeneRx BiopharmaceuticalsRockville, MD, USPharmaceuticals, Therapeuticsest. 1982RegeneRx BiopharmaceuticalsRockville, MD, US · est. 1982

US-based RegeneRx Biopharmaceuticals specializes in commercializing Thymosin beta 4 for rapid tissue repair and regeneration.

Public · $11.7M3

NeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30

Regor TherapeuticsBoston, MA, USBiotechnologyest. 2018Regor TherapeuticsBoston, MA, US · est. 2018

Regor: A global biotech leader innovating in oncology, metabolic and autoimmune diseases.

Series D · $190M8

Leadership at AI Proteins

Chris BahlCo-Founder

Noah D. BeermanCEO

Mark AllesBoard Member

Carl NovinaCo-Founder

Similar to AI Proteins

Profluent BioBerkeley, CA, USProtein Designest. 2022Profluent BioBerkeley, CA, US · est. 2022

Profluent Bio: An AI-driven firm specializing in designing innovative proteins for industry use.

Leadership at OncoPep

Ken AndersonBoard Member

Arthur BeckerBoard Member

Similar to OncoPep

Immune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35

OncoResponseSeattle, WA, USBiomedical Servicesest. 2016OncoResponseSeattle, WA, US · est. 2016

OncoResponse Inc: A US-based biomedical services provider specializing in cancer care research and development.

Series C · $130.1M20

OncofactorSeattle, WA, USCancer Therapeuticsest. 2011OncofactorSeattle, WA, US · est. 2011

Oncofactor Corp: US-based developer of innovative cancer therapeutics disrupting tumor-immune signaling.

Series A · $3.1M1

EpiVax OncologyProvidence, RI, USCancer Vaccinesest. 2017EpiVax OncologyProvidence, RI, US · est. 2017

EpiVax Oncology: A US-based biotech firm specializing in precision cancer immunotherapy vaccines.

Pre-Seed · $1.5M5

est. 2016

CAMP4 TherapeuticsCambridge, MA, US · est. 2016

CAMP4 Therapeutics: A Massachusetts-based biotech firm specializing in disease treatment therapies.

Public · $190M84

ArvinasNew Haven, CT, USTherapeuticsest. 2013ArvinasNew Haven, CT, US · est. 2013

US-based Arvinas, Inc. develops protein degradation therapeutics for cancer and other diseases globally.

Public · $461.6M415

Differentiated TherapeuticsBoston, MA, USTPD Therapiesest. 2021Differentiated TherapeuticsBoston, MA, US · est. 2021

Distinct Therapeutics designs and develops innovative TPD therapies for patients with unmet medical needs.

ReNAgade TherapeuticsCambridge, MA, USRNA Therapeuticsest. 2021

ReNAgade TherapeuticsCambridge, MA, US · est. 2021

ReNAgade Therapeutics: Pioneering RNA-based solutions for disease treatment through innovative medication production.

Series A · $300M123

Remix TherapeuticsWatertown, MA, USTherapiesest. 2018Remix TherapeuticsWatertown, MA, US · est. 2018

Remix Therapeutics: A biotech firm innovating small molecule therapies to revolutionize disease treatment.

Series D · $211M71

Kylin TherapeuticsWest Lafayette, IN, USRNA Therapeuticsest. 2006Kylin TherapeuticsWest Lafayette, IN, US · est. 2006

Kylin Therapeutics: Harnessing RNA nanoparticle tech for innovative RNA-based disease treatments.

Amide TechnologiesCambridge, MA, USProtein Therapeuticsest. 2016

Amide TechnologiesCambridge, MA, US · est. 2016

Amide Technologies: AI-driven protein discovery and engineering for rapid, innovative therapeutics.

Series A · $16.5M7

AikiumBerkeley, CA, USProtein Therapeuticsest. 2022AikiumBerkeley, CA, US · est. 2022

Aikium Inc., a Berkeley-based software startup, innovates in protein therapeutics using synthetic biology and deep learning.

Pre-Seed · $1.7M6

AsimovBoston, MA, USBiologics, Gene Therapyest. 2017AsimovBoston, MA, US · est. 2017

Asimov, a cellular engineering firm, advances biologics and gene therapy design through synthetic biology and AI tools.

Series B · $205M111